PRTN3 and androgen insensitivity syndrome: Specifically, NE and PR3 plasma levels conjointly predict the unfavorable outcomes of AIS patients, with an additional 4.478-fold risk to have an unfavorable outcome for plasma NE concentration > 229.56 ng/mL and an additional 2.805-fold risk for plasma PR3 concentration > 388.77 ng/mL after adjustment for confounders.